474 related articles for article (PubMed ID: 34590796)
1. COVID-19 and Sepsis.
Koçak Tufan Z; Kayaaslan B; Mer M
Turk J Med Sci; 2021 Dec; 51(SI-1):3301-3311. PubMed ID: 34590796
[TBL] [Abstract][Full Text] [Related]
2. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
Soy M; Atagündüz P; Atagündüz I; Sucak GT
Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
[TBL] [Abstract][Full Text] [Related]
3. Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?
Opoka-Winiarska V; Grywalska E; Roliński J
BMC Med; 2020 Jul; 18(1):214. PubMed ID: 32664932
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune mechanisms involved in protective and pathological immunity during COVID-19.
Widjaja G; Turki Jalil A; Sulaiman Rahman H; Abdelbasset WK; Bokov DO; Suksatan W; Ghaebi M; Marofi F; Gholizadeh Navashenaq J; Jadidi-Niaragh F; Ahmadi M
Hum Immunol; 2021 Oct; 82(10):733-745. PubMed ID: 34229864
[TBL] [Abstract][Full Text] [Related]
5. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.
Yongzhi X
Emerg Microbes Infect; 2021 Dec; 10(1):266-276. PubMed ID: 33522893
[TBL] [Abstract][Full Text] [Related]
6. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.
Root-Bernstein R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
8. Cytokine storm in severe COVID-19 pneumonia.
Gürsoy B; Sürmeli CD; Alkan M; Satıcı C; Altunok ES; Kamat S; Demirok B; Demirkol MA; Börü A
J Med Virol; 2021 Sep; 93(9):5474-5480. PubMed ID: 33963559
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis.
Prilutskiy A; Kritselis M; Shevtsov A; Yambayev I; Vadlamudi C; Zhao Q; Kataria Y; Sarosiek SR; Lerner A; Sloan JM; Quillen K; Burks EJ
Am J Clin Pathol; 2020 Sep; 154(4):466-474. PubMed ID: 32681166
[TBL] [Abstract][Full Text] [Related]
10. Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people?
Xu K; Wei Y; Giunta S; Zhou M; Xia S
Exp Gerontol; 2021 Aug; 151():111423. PubMed ID: 34048906
[TBL] [Abstract][Full Text] [Related]
11. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
12. The amount of cytokine-release defines different shades of Sars-Cov2 infection.
Bindoli S; Felicetti M; Sfriso P; Doria A
Exp Biol Med (Maywood); 2020 Jun; 245(11):970-976. PubMed ID: 32460624
[TBL] [Abstract][Full Text] [Related]
13. Immunological and Hematological Response in COVID-19.
Słomka A; Martucci G; Raffa GM; Malvindi PG; Żekanowska E; Lorusso R; Suwalski P; Kowalewski M
Adv Exp Med Biol; 2021; 1352():73-86. PubMed ID: 35132595
[TBL] [Abstract][Full Text] [Related]
14. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
15. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.
Copaescu A; Smibert O; Gibson A; Phillips EJ; Trubiano JA
J Allergy Clin Immunol; 2020 Sep; 146(3):518-534.e1. PubMed ID: 32896310
[TBL] [Abstract][Full Text] [Related]
16. Possible mechanisms responsible for acute coronary events in COVID-19.
Sheth AR; Grewal US; Patel HP; Thakkar S; Garikipati S; Gaddam J; Bawa D
Med Hypotheses; 2020 Oct; 143():110125. PubMed ID: 32763657
[TBL] [Abstract][Full Text] [Related]
17. Haemophagocytic syndrome and COVID-19.
Retamozo S; Brito-Zerón P; Sisó-Almirall A; Flores-Chávez A; Soto-Cárdenas MJ; Ramos-Casals M
Clin Rheumatol; 2021 Apr; 40(4):1233-1244. PubMed ID: 33389315
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
Front Immunol; 2022; 13():888897. PubMed ID: 35663932
[TBL] [Abstract][Full Text] [Related]
19. Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?
Liu JM; Chi J
Exp Biol Med (Maywood); 2022 Feb; 247(4):330-337. PubMed ID: 35068219
[TBL] [Abstract][Full Text] [Related]
20. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.
Soy M; Keser G; Atagündüz P; Tabak F; Atagündüz I; Kayhan S
Clin Rheumatol; 2020 Jul; 39(7):2085-2094. PubMed ID: 32474885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
